BioVie - BIVI Short Interest Ratio & Short Volume

Short interest is the volume of BioVie shares that have been sold short but have not yet been covered or closed out. As of January 15th, traders have sold 391,600 shares of BIVI short. 5.94% of BioVie's shares are currently sold short. Learn More on BioVie's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 5.94% of BioVie's floating shares are currently sold short.

BioVie saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 391,600 shares, a decline of 14.6% from the previous total of 458,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

BioVie currently has issued a total of 30,530,000 shares. Some of BioVie's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. BioVie currently has a public float of 6,590,000 shares.

5.94% of BioVie's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to BioVie: Liminal BioSciences Inc. (0.15%), Xeris Biopharma Holdings, Inc. (4.39%), GlycoMimetics, Inc. (1.56%), Chimerix, Inc. (3.57%), Spectrum Pharmaceuticals, Inc. (2.73%), InterCure Ltd. (0.26%), Merrimack Pharmaceuticals, Inc. (6.42%), Affimed (2.76%), Ovid Therapeutics Inc. (0.39%), and Nuvectis Pharma, Inc. (0.66%).

As of the most recent reporting period, the following stocks had the largest short interest positions: Occidental Petroleum Co. ($3.43 billion), T. Rowe Price Group, Inc. ($2.26 billion), Coinbase Global, Inc. ($2.19 billion), Etsy, Inc. ($1.78 billion), Paramount Global ($1.77 billion), Old Dominion Freight Line, Inc. ($1.69 billion), United Rentals, Inc. ($1.53 billion), American Airlines Group Inc. ($1.52 billion), PG&E Co. ($1.48 billion), and Voya Financial, Inc. ($1.47 billion). View all of the most shorted stocks.

Short selling BIVI is an investing strategy that aims to generate trading profit from BioVie as its price is falling. BIVI shares are trading down $0.28 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for BioVie occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of BIVI, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BIVI, twice per month. The most recent reporting period available is January, 15 2023.